TranscriptomeSciInc

Genomics company changing patient care through molecular diagnostics and the Molecular Microscope® (MMDx®) service.

[TranscriptomeSciInc @TranscriptomeSI]

We're proud to share this concise overview of our work showcased at @ATCMeeting. The team has been driven over decades to provide improved diagnostic methods that will ultimately change patient care, & we're excited to share this glimpse into our work.
https://t.co/dn3mfVG5gO

[Transplantation @TransplantJrnl]

The Trifecta-Heart paper reports that dd-cfDNA plasma levels correlate significantly with molecular rejection with injury and macrophage infiltration after #hearttransplantation. @TranscriptomeSI #OpenAccess #TXPforAll #MedTwitter https://t.co/Yge6IQrldf

[TranscriptomeSciInc @TranscriptomeSI]

📢 New Publication Alert! 📢

Many kidney transplants labeled “no rejection” show hidden TCMR & ABMR. This subthreshold activity is linked to future rejection & graft loss. 🔬

Read more: https://t.co/DfdlHIdQl5

#MMDx #MolecularMicroscope #KidneyTransplant #Rejection #TCMR #ABMR

[TranscriptomeSciInc @TranscriptomeSI]

📢HOT OFF THE PRESS!📢 Our latest publication, a definitive review of MMDx-Kidney, is available as an Open Access article. Check it out here! 👇👇👇https://t.co/Uxd6pZTLR0 #MolecularMicroscope #MMDx #kidneytransplantation #kidneybiopsy

[TranscriptomeSciInc @TranscriptomeSI]

Join us at the @ATCMeeting for Dr. Phil Halloran's Hot Topic Debate session! #ATC2024 #ATC24 #ATC2024Philly #MMDx

[TranscriptomeSciInc @TranscriptomeSI]

Join us at the @ATCmeeting for our Poster Presentation on DDK! #ATC2024 #ATC24 #ATC2024Philly #MMDx

[TranscriptomeSciInc @TranscriptomeSI]

Join us at the @ATCMeeting for our Poster Presentation on the Trifecta-Kidney Study! #ATC2024 #ATC24 #ATC2024Philly #MMDx

[TranscriptomeSciInc @TranscriptomeSI]

Join us at the @ATCMeeting for our Poster Presentation on donor age in kidneys! #ATC2024 #ATC24 #ATC2024Philly #MMDx

[TranscriptomeSciInc @TranscriptomeSI]

Join us tomorrow at the @ATCMeeting for our Poster Presentation on the Trifecta-Kidney substudy! #ATC2024 #ATC24 #ATC2024Philly #MMDx

[TranscriptomeSciInc @TranscriptomeSI]

Join us at @ATCMeeting tomorrow for our Rapid Fire Oral on MMDx-Liver! #ATC2024 #ATC24 #ATC2024Philly #MMDx

[NEJM @NEJM]

Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/S6wvGwoQqB

@ERAkidney | #Nephrology #ERA24

[TranscriptomeSciInc @TranscriptomeSI]

(1) Halloran, P. F., et al. (1990). "The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection." Transplantation 49(1): 85-91.

[TranscriptomeSciInc @TranscriptomeSI]

We are excited to report the publication of our recent collaborative study with Vienna and Berlin, published in @nejm. @MayerKatherinaa @MatthiasDiebold @kodo_kd @FarsadE https://t.co/xU3pip4yEL

[TranscriptomeSciInc @TranscriptomeSI]

It also suggests that dd-cfDNA could be used to help manage these patients during treatment. We are committed to seeing how this agent can benefit kidney transplants with ABMR in a controlled phase 3 trial, hopefully led by our collaborators in Vienna and Berlin.

[TranscriptomeSciInc @TranscriptomeSI]

This is historic: since we first described ABMR as a microcirculation disease 34 years ago (1), this is the first controlled trial to show an agent that can suppress microcirculation inflammation.

[TranscriptomeSciInc @TranscriptomeSI]

The FELZ treatment suppressed ABMR molecular and histologic ABMR activity, particularly the NK cell genes, and suppressed dd-cfDNA.